Yttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study
نویسندگان
چکیده
منابع مشابه
Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
The increasing incidence of non-Hodgkin's lymphoma (NHL), coupled with the lack of optimal treatment options, has prompted the development of novel treatments. Of these, radioimmunotherapy is one of the most promising. Two of the radiolabeled monoclonal antibody therapies being studied in the treatment of NHL are yttrium 90 (90Y) ibritumomab tiuxetan and iodine 131 (131I) tositumomab. The radio...
متن کاملRadiation safety guidelines for radioimmunotherapy with yttrium 90 ibritumomab tiuxetan.
Radioimmunotherapy is a new cancer therapy that combines the cytotoxicity of radiation with the tumor-specific targeting of monoclonal antibodies. Yttrium 90 (Y-90) ibritumomab tiuxetan (Zevalin, IDEC Pharmaceuticals Corporation, San Diego, CA) is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL), includ...
متن کاملRadiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin).
Radioimmunotherapy is a recently approved treatment modality for non-Hodgkin's lymphoma that enables physicians to target cytotoxic localized radiation to tumor sites without using external-beam sources. Because it uses a pure beta emitter for therapy, (90)Y ibritumomab tiuxetan can be safely and routinely administered in an outpatient procedure, with few discharge instructions, and minimal ris...
متن کاملRadioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
The clinical development and US Food and Drug Administration approval in 1997 of the monoclonal anti-CD20 antibody rituximab have been major treatment advances for patients with B-cell non-Hodgkin's lymphoma (NHL). Rituximab produces responses in approximately 50% of cases of relapsed, low grade NHL. Most of these responses are partial remissions; cure remains elusive. One way to enhance the ef...
متن کاملImaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Yttrium 90 ibritumomab tiuxetan consists of the murine monoclonal antibody ibritumomab securely bound to the second-generation chelator tiuxetan, which attaches the high-energy pure beta emitter (90)Y, for therapy, or the gamma emitter indium 111, for imaging. The biodistribution of the therapeutic dose of (90)Y ibritumomab tiuxetan can be predicted by using an imaging dose of the antibody labe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2015
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v126.23.5108.5108